AL

Alpa Laboratories Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Alpa Laboratories Q2 Results 2026: Net loss ₹2 Cr, Revenue ₹31 Cr

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Revenue
₹31Cr
+18% YoY
+29.5% QoQ
Net profit
−₹2Cr
Q2 FY26: ₹0 Cr
Margin
−7.2%
+1.3 pp YoY
+9.3 pp QoQ

Based on Alpa Laboratories Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

Price₹56
Market cap₹124 Cr
P/E30.6

The short version

Reported revenue from operations for the quarter ended 30th September 2026:. EBITDA for the quarter ended September 30, 2026: ₹684.1 million (Standalone) and ₹677.4 million (Consolidated); down 10.2% YoY Consolidated.

From Alpa Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 15 Nov 2026.

How did Alpa Laboratories' revenue grow in the September 2026 quarter?

  • Reported revenue from operations for the quarter ended 30th September 2026:
  • Standalone: ₹3,097.56 lacs
  • Consolidated: ₹3,097.56 lacs
  • Year-on-year change in revenue from operations:
  • Standalone: Increased from ₹2,563.21 lacs (Sep 25) to ₹3,097.56 lacs (Sep 26)
  • Consolidated: Increased from ₹2,625.75 lacs (Sep 25) to ₹3,097.56 lacs (Sep 26)
  • Other income (including unrealized profits from fair value gains):

2 more points from Alpa Laboratories Ltd's call on revenue

Create a free account to keep reading this call

What happened to Alpa Laboratories' margins in Q2 FY27?

EBITDA for the quarter ended September 30, 2026: ₹684.1 million (Standalone) and ₹677.4 million…

Locked: what Alpa Laboratories Ltd said on margins

Also locked on this page: fundraising, order book

Free account, 30 seconds. No card needed.

What capex is Alpa Laboratories planning?

The presentation states the following on capex, capacity expansion, and new projects: - Capital work-in-progress as of Sep-26 stands at Rs. 74.12 lacs (Page 4). - Property, Plant & Equipment investment of Rs. 2,075.13 lacs as of Sep-26. - Capital expenditure during Sep-26 includes Rs. 70.57 lacs on property, plant, and equipment (Page 5).

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Alpa Laboratories raising money or cutting debt?

However, it provides details on borrowings and related cash flows:

Locked: what Alpa Laboratories Ltd said on fundraising

Also locked on this page: margins, order book

Free account, 30 seconds. No card needed.

How big is Alpa Laboratories' order book?

See what Alpa Laboratories Ltd said on order book & pipeline — free account, 30 seconds.

Alpa Laboratories Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Alpa Laboratories Ltd Q2 FY27 results — key figures

Alpa Laboratories Ltd Q2 FY27 reported results vs Q2 FY26, ₹ crore
₹ CrQ2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue3126+18%24+29.5%
Operating profit (EBITDA)-2-2—-4—
Operating margin-7.2%-8.5%+1.3 pp-16.5%+9.3 pp
Profit before tax-20-1781.8%1-288.8%
Net profit (PAT)-20-1781.8%1-288.8%
EPS (₹)-0.850.05-1800%0.49-273.5%

Source: Alpa Laboratories Ltd's results filing to NSE (consolidated), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹31 Cr, net loss ₹2 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

More Q2 FY27 results in Pharmaceuticals & Biotechnology

All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings

Others in Pharmaceuticals & Biotechnology this season

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

  • Aarey Drugs (Q2 FY27)

    Revenue from Operations for quarter ended 30.09.2026: ₹2,865.24 Lakhs . Key results statement takeaways from Aarey Drugs & Pharmaceuticals Ltd's Q2 FY27 results

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Alpa Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Alpa Laboratories Ltd Q2 FY27 results?

Reported revenue from operations for the quarter ended 30th September 2026:. EBITDA for the quarter ended September 30, 2026: ₹684.1 million (Standalone) and ₹677.4 million (Consolidated); down 10.2% YoY Consolidated.

What is Alpa Laboratories Ltd share price analysis?

Alpa Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 30.6 with a market cap of ₹124 Cr. Investors should review the full earnings analysis for detailed insights.

Is Alpa Laboratories Ltd planning capital expenditure?

The presentation states the following on capex, capacity expansion, and new projects:.

Keep Alpa Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.